Provectus Biopharmaceuticals Stock Market Value
| PVCT Stock | USD 0.06 0 1.67% |
| Symbol | Provectus |
Provectus Biopharmaceutica 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Provectus Biopharmaceutica's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Provectus Biopharmaceutica.
| 06/29/2025 |
| 12/26/2025 |
If you would invest 0.00 in Provectus Biopharmaceutica on June 29, 2025 and sell it all today you would earn a total of 0.00 from holding Provectus Biopharmaceuticals or generate 0.0% return on investment in Provectus Biopharmaceutica over 180 days. Provectus Biopharmaceutica is related to or competes with Defence Therapeutics, Cynata Therapeutics, Starpharma Holdings, Celyad Oncology, and Microbix Biosystems. Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicine... More
Provectus Biopharmaceutica Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Provectus Biopharmaceutica's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Provectus Biopharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 32.52 | |||
| Value At Risk | (9.38) | |||
| Potential Upside | 11.29 |
Provectus Biopharmaceutica Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Provectus Biopharmaceutica's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Provectus Biopharmaceutica's standard deviation. In reality, there are many statistical measures that can use Provectus Biopharmaceutica historical prices to predict the future Provectus Biopharmaceutica's volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (1.08) | |||
| Treynor Ratio | (0.63) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Provectus Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Provectus Biopharmaceutica Backtested Returns
Provectus Biopharmaceutica maintains Sharpe Ratio (i.e., Efficiency) of -0.0772, which implies the firm had a -0.0772 % return per unit of risk over the last 3 months. Provectus Biopharmaceutica exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Provectus Biopharmaceutica's Coefficient Of Variation of (1,371), variance of 38.37, and Risk Adjusted Performance of (0.04) to confirm the risk estimate we provide. The company holds a Beta of 0.74, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Provectus Biopharmaceutica's returns are expected to increase less than the market. However, during the bear market, the loss of holding Provectus Biopharmaceutica is expected to be smaller as well. At this point, Provectus Biopharmaceutica has a negative expected return of -0.48%. Please make sure to check Provectus Biopharmaceutica's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Provectus Biopharmaceutica performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.15 |
Insignificant reverse predictability
Provectus Biopharmaceuticals has insignificant reverse predictability. Overlapping area represents the amount of predictability between Provectus Biopharmaceutica time series from 29th of June 2025 to 27th of September 2025 and 27th of September 2025 to 26th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Provectus Biopharmaceutica price movement. The serial correlation of -0.15 indicates that less than 15.0% of current Provectus Biopharmaceutica price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.15 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Provectus Biopharmaceutica lagged returns against current returns
Autocorrelation, which is Provectus Biopharmaceutica otc stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Provectus Biopharmaceutica's otc stock expected returns. We can calculate the autocorrelation of Provectus Biopharmaceutica returns to help us make a trade decision. For example, suppose you find that Provectus Biopharmaceutica has exhibited high autocorrelation historically, and you observe that the otc stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Provectus Biopharmaceutica regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Provectus Biopharmaceutica otc stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Provectus Biopharmaceutica otc stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Provectus Biopharmaceutica otc stock over time.
Current vs Lagged Prices |
| Timeline |
Provectus Biopharmaceutica Lagged Returns
When evaluating Provectus Biopharmaceutica's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Provectus Biopharmaceutica otc stock have on its future price. Provectus Biopharmaceutica autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Provectus Biopharmaceutica autocorrelation shows the relationship between Provectus Biopharmaceutica otc stock current value and its past values and can show if there is a momentum factor associated with investing in Provectus Biopharmaceuticals.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Provectus OTC Stock Analysis
When running Provectus Biopharmaceutica's price analysis, check to measure Provectus Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Provectus Biopharmaceutica is operating at the current time. Most of Provectus Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Provectus Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Provectus Biopharmaceutica's price. Additionally, you may evaluate how the addition of Provectus Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.